Research Topics
| DOUGLAS A HANAHANSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancerDouglas Hanahan
Department of Biochemistry and Biophysics, Diabetes Center, and Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA 94143, USA
Genes Dev 21:2258-70. 2007....- Retrospective: Judah Folkman (1933-2008)Douglas Hanahan
Department of Biochemistry and Biophysics, University of California-San Francisco, San Francisco, CA 94143, USA
Science 319:1055. 2008 
Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancerZhu Alexander Cao
Department of Biochemistry, Diabetes and Comprehensive Cancer Centers, University of California at San Francisco, San Francisco, CA 94143 0534, USA
BMC Cancer 2:11. 2002..Thus, an important goal for tumor immunotherapy is to identify ways to modulate in vivo anti-tumor immunity to achieve clinical efficacy. We investigate this proposition in a spontaneous mouse tumor model, Rip1-Tag2...- Peripheral-antigen-expressing cells in thymic medulla: factors in self-tolerance and autoimmunityD Hanahan
Department of Biochemistry and Biophysics Hormone Research Institute University of California at San Francisco CA 94143 0534 USA
Curr Opin Immunol 10:656-62. 1998..Thymus transplantation demonstrates a functional capability of such expression for self-tolerance induction. Correlative studies suggest that impaired thymic expression confers susceptibility to autoimmune disease... - A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancerKristian Pietras
Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California San Francisco, 513 Parnassas Avenue, San Francisco, CA 94143, USA
J Clin Oncol 23:939-52. 2005.... - MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancerPeter Olson
Diabetes Center, University of California at San Francisco, San Francisco, California 94143, USA
Genes Dev 23:2152-65. 2009..Many of the miR changes associated with specific stages and hallmark capabilities in the mouse model are similarly altered in human tumors, including cognate pancreatic neuroendocrine tumors, implying a generality... - Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapyDanielle B Ulanet
Department of Biochemistry and Biophysics, Diabetes Center, University of California, San Francisco, CA 94143, USA
Proc Natl Acad Sci U S A 107:10791-8. 2010..The results predict that elevated IR signaling before and after treatment will respectively manifest intrinsic and adaptive resistance to anti-IGF-1R therapies... - Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesisHiroaki Nozawa
Diabetes and Comprehensive Cancer Centers, University of California, San Francisco, CA 94143, USA
Proc Natl Acad Sci U S A 103:12493-8. 2006..Thus infiltrating neutrophils can play a crucial role in activating angiogenesis in a previously quiescent tissue vasculature during the early stages of carcinogenesis... - Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targetingKristian Pietras
Department of Biochemistry and Biophysics, Diabetes Center and Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States ofAmerica
PLoS Med 5:e19. 2008..We postulated that pharmacological targeting of putative stromal support functions, in particular those of cancer-associated fibroblasts, could have therapeutic utility, and sought to assess the possibility in a pre-clinical setting... - Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesisJohanna A Joyce
Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California at San Francisco, 94143, USA
Cancer Cell 5:443-53. 2004..Cysteine cathepsins are also upregulated during HPV16-induced cervical carcinogenesis, further encouraging consideration of this protease family as a therapeutic target in human cancers... - Oncogene expression and genetic background influence the frequency of DNA copy number abnormalities in mouse pancreatic islet cell carcinomasJeffrey H Hager
Department of Biochemistry, University of California at San Francisco Diabetes and Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA
Cancer Res 64:2406-10. 2004..These studies illustrate the utility of transgenic animal models for investigation of factors influencing genomic heterogeneity despite the commonalty of target cell type and initiating oncogene... - Modes of resistance to anti-angiogenic therapyGabriele Bergers
University of California, San Francisco, Department of Neurological Surgery, Brain Tumour Research Center, San Francisco, California 94143, USA
Nat Rev Cancer 8:592-603. 2008.... - Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsGabriele Bergers
Department of Neurological Surgery, University of California, San Francisco Comprehensive Cancer Center, San Francisco, San Francisco, California 94115, USA
J Clin Invest 111:1287-95. 2003..Thus, combinatorial targeting of receptor tyrosine kinases shows promise for treating multiple stages in tumorigenesis, most notably the often-intractable late-stage solid tumor... - Loss of p19(Arf) facilitates the angiogenic switch and tumor initiation in a multi-stage cancer model via p53-dependent and independent mechanismsDanielle B Ulanet
Diabetes Center, University of California San Francisco, San Francisco, California, United States of America
PLoS ONE 5:e12454. 2010..These findings demonstrate that Arf loss of function can promote tumorigenesis via facilitating angiogenesis, at least in part, through p53-independent mechanisms... - Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesisChristopher W Chiu
University of California, San Francisco, CA, USA
J Clin Oncol 28:4425-33. 2010..Toward that end, we investigated the potential benefit of dual therapeutic targeting of the epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) kinases, using a preclinical mouse model of PNET... - Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsOriol Casanovas
Department of Biochemistry and Biophysics, Comprehensive Cancer Center, and Diabetes Center, University of California, San Francisco, San Francisco, California 94143, USA
Cancer Cell 8:299-309. 2005..These other proangiogenic signals are functionally implicated in the revascularization and regrowth of tumors in the evasion phase, as FGF blockade impairs progression in the face of VEGF inhibition... - A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancerJohanna A Joyce
Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California at San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143 0534, USA
Oncogene 24:4037-51. 2005..These data encourage clinical applications of inhibitors such as PI-88 for the many human cancers where heparanase expression is elevated or mobilization of HS-binding regulatory factors is implicated... - Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesisTheresa Lopez
Department of Biochemistry and Biophysics and the UCSF Diabetes and Comprehensive Cancer Centers, University of California, San Francisco, 94143, USA
Cancer Cell 1:339-53. 2002..Notably, encapsulated tumors were absent; instead, invasive carcinomas with downregulated E-cadherin were prevalent, and the majority of mice had local lymph node metastasis... - VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesisMasahiro Inoue
Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California at San Francisco, San Francisco, CA 94143, USA
Cancer Cell 1:193-202. 2002..Thus, VEGF-A is crucial for angiogenesis in a prototypical model of carcinogenesis, whose loss is not readily compensated... - An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesisEnrico Giraudo
Department of Biochemistry and Biophysics, Diabetes Center, and Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA
J Clin Invest 114:623-33. 2004.... - Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesisJohanna A Joyce
Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
Cancer Cell 4:393-403. 2003..One peptide is homologous with pro-PDGF-B, which is expressed in endothelial cells, while its receptor is expressed in pericytes... - Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelatorSeiko Ishida
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA
Cancer Cell 17:574-83. 2010..Our results identify the copper transporter as a therapeutic target, which can be manipulated with copper chelating drugs to selectively enhance the benefits of platinum-containing chemotherapeutic agents... - Immune enhancement of skin carcinogenesis by CD4+ T cellsDylan Daniel
Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California at San Francisco, 94143, USA
J Exp Med 197:1017-28. 2003..The data reveal an unexpected capability of CD4 T cells, whereby, proinflammatory CD4+ T cells, apparently responding to bacterial infection of dysplastic skin lesions, can inadvertently enhance neoplastic progression to invasive cancer... - Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil responseJessica C Pahler
Department of Biochemistry and Biophysics, Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
Neoplasia 10:329-40. 2008..If such tumor-promoting macrophages are suppressed, MMP-9(+) neutrophils are then recruited, providing alternative paracrine support for tumor angiogenesis and progression... - Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesisOriol Casanovas
Department of Biochemistry and Biophysics, Diabetes Center and Comprehensive Cancer Center, University of California San Francisco, 94143, USA
Oncogene 24:6597-604. 2005.... - Genetic ablation of Bcl-x attenuates invasiveness without affecting apoptosis or tumor growth in a mouse model of pancreatic neuroendocrine cancerJeffrey H Hager
Diabetes and Hellen Diller Family Comprehensive Cancer Centers, Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, United States of America
PLoS ONE 4:e4455. 2009.... - Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesisMatthew G H Chun
Department of Biochemistry and Biophysics, Diabetes Center, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
Proc Natl Acad Sci U S A 107:17268-73. 2010..Collectively, our results demonstrate that tumor invasion is subject to polymorphic genetic control and identify Alk as a genetic modifier of invasive tumor growth... - Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoringDonald M McDonald
University of California at San Francisco, San Francisco, CA, USA
J Immunother (1997) 27:161-75. 2004..The third addressed the translation to the clinic and monitoring of antiangiogenic activity of agents in patients and novel trial designs. What follows is a summary of the discussions and findings of each session... - Absence of telomerase and shortened telomeres have minimal effects on skin and pancreatic carcinogenesis elicited by viral oncogenesDavid Argilla
Department of Biochemistry and Biophysics, Diabetes Center, and Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA
Cancer Cell 6:373-85. 2004.... - Fourteenth Annual Pezcoller Symposium: the novel dichotomy of immune interactions with tumorsDouglas Hanahan
University of California at San Francisco, San Francisco, California 94143, USA
Cancer Res 63:3005-8. 2003..The symposium was concluded with an overall discussion focused on basic questions related to the capability of immunity to exert tumor-favoring or antitumor effects depending on conditions determined by both tumor and host functions... - Multiple roles for cysteine cathepsins in cancerJohanna A Joyce
Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California at San Francisco, San Francisco, California, USA
Cell Cycle 3:1516-619. 2004.... - CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancerDylan Daniel
Department of Biochemistry, Diabetes Center and Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143-0534, USA
Cancer Res 65:2018-25. 2005..Thus, an HPV16 E7 immunogen holds promise for noninvasive treatment and prevention of human cervical cancer... - GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformationOlivier Nolan-Stevaux
Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA
Genes Dev 23:24-36. 2009....
Research Grants
- Immune Enhancement and Therapy of CancerDouglas Hanahan; Fiscal Year: 2007..A remarkable group of tumor biologists and immunologists has been assembled to pursue these strategic goals with their collectively enabling and complementary expertise. ..